mercredi 27 juin 2018

Onco Actu du 27 juin 2018

2.6 Etiologie - Environnement

Flight crew have higher rates of some cancers, study finds [The Guardian]

3.1 Prévention - Tabac

Price of Pfizer's smoking-cessation drug Chantix doubles in just 5 years: report [FiercePharma]

4.9 Dép., diag. & prono. - Sein

New Study Confirms Higher Cancer Rate in Women with Dense Breast Tissue [RSNA]

5. Traitements

Outsmarting cancer – staying one step ahead of drug resistance [Institute of Cancer Research]

5.1 Traitements - Pré-clinique

Chemotherapy-induced diarrhea traced to immune cells [WUSTL]

NCI Projects Aim to Improve Tools, Pre-Clinical Models for Precision Oncology Research [Genome Web]

5.10 Traitements - Essais

Lynparza significantly delays disease progression in Phase III 1st-line SOLO-1 trial for ovarian cancer [AstraZeneca]

AstraZeneca, Merck eye wider cancer drug use after study success [Reuters]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

CAR macrophage tumor tech created by UPenn star scientists gets $53M [EndPoints]

5.12.7 Immunothérapies - vaccins

Poliovirus therapy shows early promise in patients with aggressive brain cancer but questions linger [STAT]

Doctors Try Genetically Modified Poliovirus As Experimental Brain Cancer Treatment [NPR]

Enemy turned ally: Poliovirus is used to fight brain tumors [AP]

5.2 Pharma

With AstraZeneca on its heels, J&J, AbbVie's Imbruvica speeds toward new nod in Waldenström's [FiercePharma]

5.3 Traitements - FDA, EMA, NICE...

FDA Repays Industry by Rushing Risky Drugs to Market [ProPublica]

5.3.4 Traitements - AMM (FDA, EMA,...)

Puma Biotechnology Announces Results of CHMP Reexamination of MAA for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer [Puma]

Puma Biotech says Europe likely to approve breast cancer drug [Reuters]

CHMP reverses course on neratinib, handing Puma an unexpected win on European marketing vote — shares soar [EndPoints]

6.10.1 Politiques (USA)

Senators Grill HHS’s Azar on Drug Price Cuts That Have Yet to Come [Xconomy]

Senate panel proposes $2 billion, 5.4% increase for NIH [Science]

6.6 Publications

Will Europe Lead a Global Flip to Open Access? [The Scholarly Kitchen]

6.8 Communication

Another hospital issues evidence-free marketing claims about proton beam therapy [HealthNewsReview]